top of page
רקע כהה למעלה
EverPatch tweezers - large.png

CorNeat EverPatch 

Permanent tissue-integrating ophthalmic surgical matrix

About Ophthalmic Reconstructive Surgery

Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.

Image by Olga Guryanova

CorNeat KPro

רקע כהה למעלה

CorNeat EverPatch Advantages 



Inert and non-degradable material

Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response


Ease of


Extremely easy to handle and suture


Elastic and durable (cannot be torn by the sutures)



Synthetic and therefore cannot carry or transmit disease


Thin (100 microns), minimizing risk of dellen



Reduces operating time and eye bank costs 


Eliminates complexities related to the transportation and storage of biological materials


Readily available, off-the-shelf, device



Translucent when wet

Hardly visible when implanted subconjunctivally

Eye contact9.jpg

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and nondegradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.  


The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue.

רקע כהה למעלה


Reinforcing the sclera and aiding the physical reconstruction of the ocular surface

Concealing irritating ophthalmic implants such as glaucoma tube shunts and scleral sutures, used in scleral fixations of IOLs, displacing the need for preserved tissue/collagen

Covering tissue gaps/weaknesses, resulting from either traumatic, disease related or iatrogenic damage

Eye contact5.jpg

First-In-Human (FIH) Implantation

The FIH implantation of the initial CorNeat EverPatch took place in December 2020 as part of a bilateral glaucoma tube shunt implantation. The surgery was conducted by Dr. Ike Ahmed at the Prism Eye Institute in Toronto, Canada.

The fact this patient underwent the same surgery in both eyes at the same time by the same surgeon presents a unique opportunity to compare the CorNeat EverPatch and current state of the art (scleral patch) – both used to conceal the shunt and protect the overlaying conjunctival tissue.

Below on the right, you can see the eye implanted with the scleral patch and on the left, the eye implanted with the CorNeat EverPatch, both photos were taken two months post-implantation.



Besides the clear aesthetic advantages of the CorNeat EverPatch over the scleral (tissue) patch, the device's clinical advantages are very clear. While the conjunctival tissue overlaying the CorNeat EverPatch is healthy and quiet, congestion and inflammation is clearly visible over the scleral patch – an expected reaction to donor tissue.  

28 patients were implanted with the initial configuration of the CorNeat EverPatch with promising results, thus completing the FIH clinical trial.

For more information about the FIH clinical trial click here.

Pivotal Trial
A pivotal trial for evaluating the performance of the final product is currently underway in Tbilisi, Georgia. This pivotal trial already has 12 patients implanted with the improved CorNeat EverPatch, without any safety issues. Further sites are currently being evaluated.

Immediately post-op, the CorNeat EverPatch is visible under the conjunctiva (in two different patients):

EP Pivotal - Patient 5.JPG
EP Pivotal - Patient 11.JPG

For more information about the pivotal trial click here.

רקע כהה למעלה

Regulatory Path

FDA Clearance

The CorNeat EverPatch is following a 510(k) clearance path, after submitting all necessary documents to the FDA in September 2022. The 510(k) submission is based on numerous tests and assessments which include a long-term animal trial, usability assessment and numerous R&D tests. The device is expected to be approved for marketing in the US and in FDA adopting countries early in 2023, with the following intended use: implantation to reinforce the sclera and aid the physical reconstruction of the ocular surface.

CE Marking

The current pivotal trial is geared toward obtaining a CE Marking early in 2024, for wider indications that include: the concealment of artificial ophthalmic implants, such as glaucoma shunts and scleral sutures used in scleral fixations of IOLs, from the overlying conjunctiva.

The plans above are subject to regulatory approvals and requirements.

Anchor 1
Product Animation 
bottom of page